v3.25.2
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended 56 Months Ended
Nov. 03, 2020
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jun. 30, 2025
Disaggregation of Revenue [Line Items]                  
Payments for loan acquisition costs           $ 14 $ 10    
Revenues   $ 10,003 $ 20,099     18,723 $ 32,152    
Royalty                  
Disaggregation of Revenue [Line Items]                  
Revenues           $ 914   $ 1,008  
MAM Pangolin Royalty , LLC | Maximum                  
Disaggregation of Revenue [Line Items]                  
Proceeds from sale of future revenue $ 125,000                
License agreement with Sunovion Pharmaceuticals, Inc.                  
Disaggregation of Revenue [Line Items]                  
Minimum annual royalty receivable         $ 1,000        
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty                  
Disaggregation of Revenue [Line Items]                  
Revenues       $ 8,000 $ 8,000        
Monetization Agreement                  
Disaggregation of Revenue [Line Items]                  
Payments for loan acquisition costs $ 2,909                
Effective annual interest rate 24.90%                
Monetization Agreement | MAM Pangolin Royalty , LLC                  
Disaggregation of Revenue [Line Items]                  
Proceeds from sale of future revenue $ 40,000               $ 50,000
Additional proceeds from sale of future revenue 10,000                
Proceeds from debt, contingent on additional milestones $ 75,000